myEarthLink
News

Weather  

 

The Weather Channel
Clear
60° F
New York, NY
Clear
Hi: 76° / Lo: 55°

Sports   edit

nhl - Scoreboard [hide]

Thursday, October 19, 2017
Final
Friday, October 20, 2017
San Jose Sharks (2-3-0) at
Preview
Friday, October 27, 2017
Ottawa Senators (3-1-3) at
Preview

nba - Scoreboard [hide]

Wednesday, October 18, 2017
Final
No Games Scheduled
Saturday, October 21, 2017
Preview

nfl - Scoreboard [hide]

Sunday, October 15, 2017
Final
No Games Scheduled
Sunday, October 29, 2017
Preview
Sunday, October 22, 2017
Preview

mlb - Scoreboard [hide]

Wednesday, October 18, 2017
Houston Astros (101-61) at
Final
Friday, October 20, 2017
New York Yankees (91-71) at
Preview
Saturday, October 21, 2017
New York Yankees (91-71) at
Preview

Market Update  

- By Mitch Tuchman A nudge is great, but sometimes, the best thing to do is nothing Richard Thaler, the recent winner of the Nobel Prize for economics, is a brilliant man. Anyone interested...
More

MarketWatch

 
Sign In to get personalized news, weather and more at myEarthLink.
 

Printable View

Merck scraps disappointing experimental cholesterol drug
FILE - In this Dec. 18, 2014, file photo, a person walks through a Merck company building in Kenilworth, N.J. Merck has decided to abandon efforts to market a closely watched experimental cholesterol medicine after mediocre test results. Merck's decision Wednesday, Oct. 11, 2017, to not seek regulatory approval after years of testing marks the fourth time this type of once-promising drug has been scrapped. (AP Photo - Mel Evans)
By LINDA A. JOHNSON
From Associated Press
October 11, 2017 6:31 PM EST

TRENTON, N.J. (AP) — Merck has decided to abandon efforts to market a closely watched experimental cholesterol medicine after mediocre test results.

Merck's decision Wednesday to not seek regulatory approval after years of testing marks the fourth time this type of once-promising drug has been scrapped. Merck had continued to study its drug, a so-called CETP inhibitor called anacetrapib, long after rivals had given up on similar drugs.

Merck raised hopes when it announced in June that anacetrapib not only lowered cholesterol, but also reduced heart attacks, deaths and other heart disease complications. But in August it disclosed the pill only cut those risks 9 percent.

That would have limited sales of the drug, if it had won regulatory approval, in part because cheap, genetic statin drugs lower cholesterol well for most people.

Copyright 2017 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.